---
category: news
title: "Why BioXcel Therapeutics Shares Went Up 12.9% This Week"
excerpt: "Shares of BioXcel Therapeutics (NASDAQ: BTAI), a commercial-stage biopharmaceutical company that uses artificial intelligence to develop neuroscience and immuno-oncology therapies, rose 12.9% this week,"
publishedDateTime: 2022-05-05T20:54:00Z
originalUrl: "https://www.nasdaq.com/articles/why-bioxcel-therapeutics-shares-went-up-12.9-this-week"
webUrl: "https://www.nasdaq.com/articles/why-bioxcel-therapeutics-shares-went-up-12.9-this-week"
ampWebUrl: "https://www.nasdaq.com/articles/why-bioxcel-therapeutics-shares-went-up-12.9-this-week?amp"
cdnAmpWebUrl: "https://www-nasdaq-com.cdn.ampproject.org/c/s/www.nasdaq.com/articles/why-bioxcel-therapeutics-shares-went-up-12.9-this-week?amp"
type: article
quality: 54
heat: 64
published: false

provider:
  name: Nasdaq
  domain: nasdaq.com

topics:
  - AI in Healthcare
  - AI

related:
  - title: "BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights"
    excerpt: "Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Top-line data readout in Q4 2022/early Q1 2023 for TRANQUILITY II Phase 3 trial evaluating BXCL501 in acute treatment of agitation associated with Alzheimer’s disease Extended cash runway into 2025 with $260 million strategic financing for IGALMI commercial launch and clinical and regulatory milestones U."
    publishedDateTime: 2022-05-09T11:03:00Z
    webUrl: "https://apnews.com/press-release/globe-newswire/covid-technology-health-business-mental-3717bf59c739265c231f90dcf287f725"
    type: article
    provider:
      name: Associated Press
      domain: apnews.com
    quality: 10
    images:
      - url: "https://apnews.com/images/PaidContent3.png"
        width: 700
        height: 450
        isCached: true

secured: "vX1BK1TU5xrj9vtiOUJP1al+qepe4DtVySfvY0WfB++Dq6DIJ+QfiqUftR4fIc6E6c4bzP5kn787LCbqnZ/hq+CDlBy2gvgMDC6CiROCTIhTiaiLlL9RxatWU+CWPY523fWbLzJ86BtuGNkCwZoHy+Pefh2lnQdZf/EjCFIXW28c1dc3HXUoiPL0olIkurYC5LHnkkc06qMRu1asCsianTklD6cjT/SNsi8bd3l3flRs/+WJYnTmSFRqIaUAbtCuGGIMlnu81iatMhy20ZYitE2mA9g82AwA3zXo7YFnhblvNSb15OLrMKkuu5jJ8IuIJD7cVvgz4ft7Y8N0aRAMQf9mGYeG5CBheXFEtusN4Gs=;pmCyoa0EZa7OgUEUx/R/IQ=="
---

